Skip to main content

Table 2 The fold change of cell proliferation in day 5 of each EGFR mutation compared to day 0 and IC50 value of erlotinib treatment in each EGFR mutations

From: HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant

EGFR mutationsFold change of cell proliferationIC50 value (μM)
Without EGFWith EGFErlotinib
pBabe6.1 ± 0.77.3 ± 1.27.95 ± 0.4
WT7.7 ± 1.211.4 ± 2.211.97 ± 1.8
T790M12.0 ± 1.214.2 ± 1.515.16 ± 1.3
L858R16.0 ± 1.619.3 ± 0.80.07 ± 0
K757E7.5 ± 1.811.3 ± 3.124.67 ± 2.1
N808S10.0 ± 2.312.1 ± 2.813.26 ± 5.3
R831C7.1 ± 1.510.8 ± 3.28.47 ± 0.5
V897A10.6 ± 2.512.5 ± 2.919.78 ± 3.3
P937L11.3 ± 2.112.0 ± 1.212.32 ± 4.2
T940A9.8 ± 2.313.2 ± 3.95.58 ± 0.4
M947T9.5 ± 2.211.5 ± 3.212.3 ± 1.2
  1. IC50 values for erlotinib in EGFR mutants were calculated by using the data from Fig. 3